BPC-157 / TB-500 / KPV
Tri-Peptide Research Blend - BPC-157, TB-500 and KPV co-formulated in a single vial.
A co-formulated blend pairing BPC-157, TB-500 and KPV at 10mg each, prepared for researchers studying repair signaling and the KPV anti-inflammatory pathway together in one preparation.
This preparation extends the familiar BPC-157 / TB-500 pairing with KPV, so a single vial covers angiogenic, cytoskeletal and anti-inflammatory signaling. Laboratories typically use it when those routes are being studied together and separate reconstitution of three compounds would add handling variability.
BPC-157 / TB-500 / KPV specifications
- Molecular formula
- Co-formulated blend
- Sequence
- BPC-157 10mg + TB-500 10mg + KPV 10mg
- Residues
- BPC-157 + TB-500 + KPV
- Presentation
- Lyophilized powder
- Documented purity
- 99.04% by HPLC
- Available sizes
- 30mg ($145)
- Archived COA lots
- 1
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Combined repair signaling - Investigated for overlapping angiogenic and actin-regulating activity of BPC-157 and TB-500 when studied together.
- Inflammatory signaling - The KPV arm is studied for anti-inflammatory signaling in epithelial and immune-cell models.
Reported mechanisms in the literature
- BPC-157 + TB-500 - Studied for complementary angiogenic and actin-regulating activity when the two repair peptides are examined together. (Combination research)
- KPV arm - KPV, the C-terminal tripeptide of α-MSH, is studied for anti-inflammatory signaling in epithelial and immune-cell models. (Preclinical literature)
What BPC-157 / TB-500 / KPV is researched for
- Combined repair signaling - Studied for the combined angiogenic and actin-regulating activity of BPC-157 and TB-500. (Combination research)
- KPV pathway - Investigated for KPV's anti-inflammatory signaling alongside the repair peptides. (Preclinical literature)
BPC-157 / TB-500 / KPV certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| 8HEX09 | 9 Oct 2026 | 30mg | Freedom Diagnostics | 99.04% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on BPC-157 / TB-500 / KPV
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
BPC-157 / TB-500 / KPV frequently asked questions
What is in this blend?
BPC-157, TB-500 and KPV, 10mg each, co-formulated in a single 30mg vial.
Is it approved for human use?
No. It is a research material only, supplied for in-vitro laboratory study.
How is it documented?
Each lot ships with its Certificate of Analysis.
Documented to 99.04% purity by HPLC · third-party COA every lot · from $145 · For laboratory research use only.
Related Regenerative & Repair compounds
- BPC-157 - Synthetic pentadecapeptide studied for VEGF and growth-factor receptor signaling.
- TB-500 - Thymosin β-4 fragment studied for actin regulation and tissue repair.
- BPC-157 / TB-500 - Co-formulated repair-research blend in a single vial.
- GHK-Cu - Copper tripeptide studied in skin-remodeling research.
- KPV - α-MSH C-terminal fragment studied for inflammatory signaling.
- ARA-290 - Erythropoietin-derived peptide studied for neural repair.